In vitro evaluation of the clastogenicity of fumagillin

Environmental and Molecular Mutagenesis

Volumn 49, Issue 8, 2008, Pages 594-601

  Stevanovic, Jevrosima ^a   Stanimirovic, Zoran ^a   Radakovic, Milena ^a   Stojic, Velibor ^a  

^a UNIVERSITY OF BELGRADE   (Serbia)

Author keywords

Chromosome aberrations; Fumagillin dicyclohexylamine salt; Micronucleus assay; Sister chromatid exchanges

Indexed keywords

ANTIBIOTIC AGENT; FUMAGILLIN; FUMAGILLIN DICYCLOHEXYLAMINE SALT; FUMAGILLIN ET; UNCLASSIFIED DRUG;

ARTICLE; CALCULATION; CELL PROLIFERATION; CHROMOSOME ABERRATION; COMPARATIVE STUDY; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOTOXICITY; HUMAN; HUMAN CELL; LYMPHOCYTE CULTURE; MICRONUCLEUS; MITOSIS; NUCLEAR DIVISION; PERIPHERAL LYMPHOCYTE; SISTER CHROMATID EXCHANGE;

ANALYSIS OF VARIANCE; CELLS, CULTURED; CHROMOSOME ABERRATIONS; CYCLOHEXANES; DOSE-RESPONSE RELATIONSHIP, DRUG; FATTY ACIDS, UNSATURATED; HUMANS; MICRONUCLEUS TESTS; MUTAGENICITY TESTS; MUTAGENS; SESQUITERPENES; SISTER CHROMATID EXCHANGE;

ASPERGILLUS FUMIGATUS; MAMMALIA; MICROSPORIDIA;

EID: 54249107151     PISSN: 08936692     EISSN: 10982280     Source Type: Journal    
DOI: 10.1002/em.20409     Document Type: Article

References (67)

1. Albertini RJ, Anderson D, Douglas GR, Hagmar L, Hemminki K, Merlo F, Natarajan AT, Norppa H, Shuker DEG, Tice R, Waters MD, Aitio A. 2000. IPCS guidelines for the monitoring of genotoxic effects of carcinogens in humans. Mutat Res 463:111-172.
2. Assil H, Sporns P. 1991. ELISA and HPLC methods for analysis of fumagillin and its decomposition products in honey. J Agric Food Chem 39:2206-2213.
3. Athanassopoulou F, Karagouni E, Dotsika E, Ragias V, Tavla J, Christofilloyanis P, Vatsos I. 2004. Efficacy and toxicity of orally administrated anti-coccidial drugs for innovative treatments of Myxobolus sp. infection in Puntazzo puntazzo. Dis Aquat Organ 62:217-226.
4. Bailey L. 1953. Effect of fumagillin upon Nosema apis (Zander). Nature 171:212-213.
5. Bernier SG, Taghizaeh N, Thompson CD, Westlin WF, Hannig G. 2005. Methionine aminopeptidases type I, type II are essential to control cell proliferation. J Cell Biochem 95:1191-1203.
6. Bonassi S, Ugolini D, Kirsch-Volders M, Strömberg U, Vermeulen R, Tucker JD. 2005. Human population with cytogenetic biomarkers: Review of the literature and future prospectives. Environ Mol Mutagen 45:258-270.
7. Bonassi S, Znaor A, Ceppi M, Lando C, Chang WP, Holland N, Kirsch-Volders M, Zeiger E, Ban S, Barale R, Bigatti MP, Bolognesi C, Cebulska-Wasilewska A, Fabianova E, Fucic A, Hagmar L, Joksic G, Martelli A, Migliore L, Mirkova E, Scarfi MR, Zijno A, Norppa H, Fenech M. 2007. An increased micronucleus frequency in peripheral blood lymphocytes predicts the risk of cancer in humans. Carcinogenesis 28:625-631.
8. Conteas CN, Berlin OG, Ash LR, Pruthi JS. 2000. Therapy for human gastrointestinal microsporidiosis. Am J Trop Med Hyg 63:121-127.
9. Diesenhouse MC, Wilson LA, Corrent GF, Visvesvara GS, Grossniklaus HE, Bryan RT. 1993. Treatment of microsporidial keratoconjunctivitis with topical fumagillin. Am J Ophthalmol 115:293-298.
10. Eastmond DA, Tucker JD. 1989. Identification of aneuploidy-inducing agents using cytokinesis-blocked human lymphocytes and an antikinetochore antibody. Environ Mol Mutagen 13:34-43.
11. Eastmond DA, Schuler M, Rupa DS. 1995. Advantages and limitations of using fluorescence in situ hybridisation for the detection of aneuploidy in interphase human cells. Mutat Res 348:153-162.
12. EMEA. 2000. The European Agency for the Evaluation of Medicinal Products, Veterinary Medicines and Information Technology, EMEA/CVMP/411/00-FINAL, Committee for Veterinary Medicinal Products, Update of the Position Paper on Availability of Veterinary Medicines 21 June, 2000. Available at: http://www.emea.europa.eu/pdfs/vet/press/pp/041100en.pdf.
13. EMEA. 2007. European Medicines Agency Pre-authorisation Evaluation of Medicines for Human Use. Document Date: London, 29 May 2007, Doc.Ref.: EMEA/COMP/82/02 Rev. 2, Committee for orphan medicinal products. Public summary of positive opinion for orphan designation of fumagillin for the treatment of diarrhoea associated with intestinal microsporidial infection. Available at: http://www.emea.europa.eu/pdfs/human/comp/opinion/008202en.pdf.
14. Evans HJ. 1984. Human peripheral blood lymphocytes for the analysis of chromosome aberrations in mutagen tests. In: Kilbey BJ, Legator M, Nichols W, Ramel C, editors. Handbook of Mutagenicity Test Procedures,2nd ed. Amsterdam: Elsevier Science. pp 405-427.
15. Fenech M, Morley AA. 1985. Measurement of micronuclei in lymphocytes. Mutat Res 147:29-36.
16. Furgala B, Sugden MA. 1985. Residual activity of bicyclohexylammonium fumagillin in sucrose syrup and high fructose corn syrup stored at two temperatures. Am Bee J 125:47-48.
17. Ghosh D, Lalitkumar PG, Wong V, Dhawan L, Rosario JF, Hendrickx AG, Lasley BL, Overstreet JW, Sengupta J. 2001. Effect of vaginally administered fumagillin on the morphology of implantation stage endometrium in the rhesus monkey. Contraception 63:95-102.
18. Griffith EC, Su Z, Turk BE, Chen S, Chang YH, Wu Z, Biemman K, Liu JO. 1997. Methionine aminopeptidases (type II) is the common target for angiogenesis inhibitors AGM-1470 and ovalicin. Chem Biol 4:461-471.
19. Griffith EC, Su Z, Niwayama S, Ramsay CA, Chang YH, Liu JO. 1998. Molecular recognition of angiogenesis inhibitors fumagillin and ovalicin by methionine aminopeptidase-2. Proc Natl Acad Sci USA 95:15183-15188.
20. Hedrick RP, Groff JM, McDowell T. 1988. Oral administration of Fumagillin DCH protects chinook salmon Oncorhynchus tshawytscha from experimentally-induced proliferative kidney disease. Dis Aquat Organ 4:165-168.
21. Ingber D, Fujita T, Kishimoto S, Sudo K, Kanamaru T, Brem H, Folkman J. 1990. Synthetic analogues of fumagillin that inhibit angiogenesis and suppress tumour growth. Nature 348:555-557.
22. Kastan MB, Onyekwere O, Sidransky D, Vogelstein B, Craig RW. 1991. Participation of p53 protein in the cellular response to DNA damage. Cancer Res 51:6304-6311.
23. Katznelson H, Jamieson CA. 1952. Control of Nosema disease of honeybees with fumagillin. Science 115:70-71.
24. Kent ML, Dawe SC. 1994. Efficacy of fumagillin Dch against experimentally induced Loma salmonae (Microsporea) infections in chinook salmon Oncorhynchus tshawytscha. Dis Aquat Organ 20:231-233.
25. Kim S, LaMontagne K, Sabio M, Sharma S, Versace RW, Yusuff N, Phillips PE. 2004. Depletion of methionine aminopeptidase 2 does not alter cell response to fumagillin or bengamides. Cancer Res 64:2984-2987.
26. Kirkland D, Pfuhler S, Tweats D, Aardema M, Corvi R, Darroudi F, Elhajouji A, Glatt H, Hastwell P, Hayashi M, Kasper P, Kirchner S, Lynch A, Marzin D, Maurici D, Meunier J-R, Müller L, Nohynek G, Parry J, Parry E, Thybaud V, Tice R, van Benthem J, Vanparys P, White P. 2007. How to reduce false positive results when undertaking in vitro genotoxicity testing and thus avoid unnecessary follow-up animal tests: Report of an ECVAM Workshop. Mutat Res 628:31-55.
27. Kirsch-Volders M, Elhajouji A, Cundari E, Van Hummelen P. 1997. The in vitro micronucleus test: A multi-endpoint assay to detect simultaneously mitotic delay, apoptosis, chromosome breakage, chromosome loss and non-disjunction. Mutat Res 392:19-30.
28. Kulic M. 2006. Investigations of genotoxic potential od dicyclohexylamine in vivo and in vitro. PhD Thesis, Department of Biology, University of Banja Luka, 2006.
29. Lambert S, Lopez BS. 2001. Role of RAD51 in sister-chromatid exchanges in mammalian cells. Oncogene 20:6627-6631.
30. Lamberti L, Bigatti-Ponzetto P, Ardito G. 1983. Cell kinetics and sister chromatid exchange frequency in human lymphocytes. Mutat Res 120:193-199.
31. Le Gouvello R, Pobel T, Richards RH, Gould C. 1999. Field efficacy of a 10-day treatment of fumagillin against proliferative kidney disease in rainbow trout Oncorhynchus mykiss. Aquaculture 17:27-40.
32. Liu TP. 1990a. Ultrastructure of mitochondria in the corpora allata of honeybees infected by Nosema apis before and after treatment with anti-Nosema drugs. Tissue Cell 22:511-515.
33. Liu TP. 1990b. Ultrastructural changes in the secretion granules of the hypopharyngeal glands of the honeybee infected by Nosema apis and after treatment with fumagillin. Tissue Cell 22:523-531.
34. Mace ML Jr, Daskal Y, Wray W. 1978. Scanning-electron microscopy of chromosome aberrations. Mutat Res 52:199-206.
35. WAF1/CIP1 mechanism. Transl Res 149:46-53.
36. Mazzanti CM, Tandle A, Lorang D, Costouros N, Roberts D, Bevilacqua G, Libutti SK. 2004. Early genetic mechanisms underlying the inhibitory effects of endostatin and fumagillin on human endothelial cells. Genome Res 14:1585-1593.
37. McCowen MC, Callender ME, Lawlis JF Jr. 1951. Fumagillin (H-3), a new antibiotic with amebicidal properties. Science 113:202-203.
38. Mitelman F, editor. 1995. ISCN 1995: An International System for Human Cytogenetic Nomenclature. Basel, Switzerland: S. Karger.
39. 2000, Budva, SRJ. pp 211-212.
40. Molina JM, Goguel J, Sarfati C, Michiels JF, Desportes-Livage I, Balkan S, Chastang C, Cotte L, Maslo C, Struxiano A, Derouin F, Decazes JM. 2000. Trial of oral fumagillin for the treatment of intestinal microsporidiosis in patients with HIV infection. AIDS 14:1341-1348.
41. Molina JM, Tourneur M, Sarfati C, Chevret S, de Gouvello A, Gobert JG, Balkan F, Derouin F. 2002. Fumagillin treatment of intestinal microsporidiosis. N Engl J Med 346:1963-1969.
42. Norppa H, Falck GC-M. 2003. What do human micronuclei contain? Mutagen 18:221-233.
43. Palitti FC, Tanzarella R, Cozzi R, Ricondy E, Vitagliana A, Fiori M. 1982. Comparison of frequencies of SCEs induced by chemical mutagens in bone-marrow spleen and spermatogoneal cells of mice. Mutat Res 103:191-195.
44. Parry EM, Parry JM, Corso C, Doherty A, Haddad F, Hermine TF, Johnson G, Kayani M, Quick E, Warr T, Williamson J. 2002. Detection and characterization of mechanisms of action of aneugenic chemicals. Mutagen 17:509-521.
45. Paz-y-Miño C, Bustamante G, Sánchez ME, Leone PE. 2002. Cytogenetic monitoring in a population occupationally exposed to pesticides in Ecuador. Environ Health Perspect 110:1077-1080.
46. Perry P, Wolff S. 1974. New Giemsa method for the differential staining of sister chromatids. Nature 251:156-158.
47. Perry PE, Thompson EJ. 1984. The methodology of sister chromatid exchanges. In: Kilbey BJ, Legator M, Nichols W, Ramel C, editors. Handbook of Mutagenicity Test Procedures, 2nd ed. Amsterdam: Elsevier Science. pp 495-529.
48. Rada V, Machova M, Huk J, Marounek M, Duskova D. 1997. Microflora in the honeybee digestive tract - Counts, characteristics and sensitivity to veterinary drugs. Apidologie 28:357-365.
49. Renzi L, Pacchierotti F, Russo A. 1996. The centromere as a target for the induction of chromosome damage in resting and proliferating cells: Assessment of mitomycin C-induced genetic damage at kinetochores and centromeres by a micronucleus test in mouse splenocytes. Mutagen 11:133-138.
50. Rodriguez-Nieto S, Medina MA, Quesada AR. 2001. A re-evaluation of fumagillin selectivity towards endothelial cells. Anticancer Res 21:3457-3460.
51. Rosberger DF, Serdarevic ON, Erlandson RA, Bryan RT, Schwartz DA, Visvesvara GS, Keenan PC. 1993. Successful treatment of microsporidial keratoconjunctivitis with topical fumagillin in a patient with AIDS. Cornea 12:261-265.
52. Sin N, Meng L, Wang MQ, Wen JJ, Bornmann WG, Crews CM. 1997. The anti-angiogenic agent fumagillin covalently binds and inhibits the methionine aminopeptidase, MetAP-2. Proc Natl Acad Sci USA 94:6099-6103.
53. Sonoda E, Sasaki MS, Morrison C, Yamaguchi-Iwai Y, Takata M, Takeda S. 1999. Sister-chromatid exchanges are mediated by homologous recombination in vertebrate cells. Mol Cell Biol 19:5166-5169.
54. Stanimirovic Z, Stevanovic J, Pejovic D. 1999. Analysis of genotoxic effects of fumagillin-ET. In: Proceedings of the 29th Annual Meeting of the European Environ Mutagen Society-EEMS-99, Vol. 85. Copenhagen, Denmark, pp 44-45.
55. Stanimirovic Z, Stevanovic J, Jovanovic S, Andjelkovic M. 2005. Evaluation of genotoxic effects of Apitol® (cymiazole hydrochloride) in vitro by measurement of sister chromatid exchange. Mutat Res 588:152-157.
56. Stanimirovic Z, Stevanovic J, Bajic V, Radovic I. 2007. Evaluation of genotoxic effects of fumagillin by cytogenetic tests in vivo. Mutat Res 628:1-10.
57. 2000, June 12-16, Budva, SRJ. pp 227-230.
58. Titenko-Holland N, Windham G, Kolachana P, Reinisch F, Parvatham S, Osorio AM, Smith MT. 1997. Genotoxicity of malathion in human lymphocytes assessed using the micronucleus assay in vitro and in vivo: A study of malathion-exposed workers. Mutat Res 388:85-95.
59. Tucker JD, Auletta A, Cimino MC, Dearfield KL, Jacobson-Kram D, Tice RR, Carrano AV. 1993. Sister chromatid exchange: Second report of Gene-Tox program. Mutat Res 297:101-180.
60. Watanabe N, Nishihara Y, Yamaguchi T, Koito A, Miyoshi H, Kakeya H, Osada H. 2006. Fumagillin suppresses HIV-1 infection of macrophages through the inhibition of Vpr activity. FEBS Lett 580:2598-2602.
61. Webster TC. 1994. Fumagillin affects Nosema apis and honey-bees (Hymenoptera: Apidae). J Econ Entomol 87:601-604.
62. Wishkovsky A, Groff JM, Lauren DJ, Toth RJ, Hedrick RP. 1990. Efficacy of fumagillin against proliferative kidney disease and its toxic side effects in rainbow trout Oncorhynchus mykiss fingerlings. Fish Pathol 25:141-146.
63. Yeh JR, Mohan R, Crews CM. 2000. The antiangiogenic agent TNP-470 requires p53 and p21WAF1/CIP1 for endothelial cell growth arrest. Proc Natl Acad Sci USA 97:12782-12787.
64. Yeh JR, Ju R, Brdlik CM, Zhang W, Zhang Y, Matyskiela ME, Shotwell JD, Crews CM. 2006. Targeted gene disruption of methionine aminopeptidase 2 results in an embryonic gastrulation defect and endothelial cell growth arrest. Proc Natl Acad Sci USA 103:10379-10384.
65. Zbinden M, Lass S, Refardt D, Hottinger J, Ebert D. 2005. Octosporea bayeri: Fumidil B inhibits vertical transmission in Daphnia magna. Exp Parasitol 109:58-61.
66. WAF1/CIP1. Proc Natl Acad Sci USA 97:6427-6432.
67. Zhang Y, Yeh JR, Mara A, Ju R, Hines JF, Cirone P, Griesbach HL, Schneider I, Slusarski DC, Holley SA, Crews CM. 2006. A chemical and genetic approach to the mode of action of fumagillin. Chem Biol 13:1001-1009.